KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$11.57 USD
+0.07 (0.61%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $11.60 +0.03 (0.26%) 5:18 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Income Statements
Fiscal Year end for KalVista Pharmaceuticals, Inc falls in the month of April .
All items in Millions except EPS data.
4/30/23 | 4/30/22 | 4/30/21 | 4/30/20 | 4/30/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 13 | 16 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 13 | 16 |
Selling & Adminstrative & Depr. & Amort Expenses | 111 | 97 | 58 | 53 | 46 |
Income After Depreciation & Amortization | -111 | -97 | -58 | -41 | -30 |
Non-Operating Income | 18 | 14 | 12 | 11 | 9 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -93 | -82 | -46 | -29 | -21 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -93 | -82 | -46 | -29 | -21 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -93 | -82 | -46 | -29 | -21 |
Depreciation Footnote | 4/30/23 | 4/30/22 | 4/30/21 | 4/30/20 | 4/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -109 | -93 | -57 | -40 | -29 |
Depreciation & Amortization (Cash Flow) | 2 | 3 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -111 | -97 | -58 | -41 | -30 |
Earnings Per Share Data | 4/30/23 | 4/30/22 | 4/30/21 | 4/30/20 | 4/30/19 |
---|---|---|---|---|---|
Average Shares | 27.89 | 24.47 | 19.09 | 17.75 | 15.08 |
Diluted EPS Before Non-Recurring Items | -3.33 | -3.36 | -2.42 | -1.64 | -1.38 |
Diluted Net EPS (GAAP) | -3.33 | -3.36 | -2.42 | -1.64 | -1.38 |
Fiscal Year end for KalVista Pharmaceuticals, Inc falls in the month of April .
All items in Millions except EPS data.
1/31/24 | 10/31/23 | 7/31/23 | 4/30/23 | 1/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 33.15 | 29.75 | 29.10 | 31.73 | 26.94 |
Income After SG&A, R&D, and Dept/Amort Expenses | -33.15 | -29.75 | -29.10 | -31.73 | -26.94 |
Non-Operating Income | 4.12 | 2.10 | 3.78 | 5.42 | 5.64 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -29.03 | -27.65 | -25.32 | -26.31 | -21.30 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -29.03 | -27.65 | -25.32 | -26.31 | -21.30 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -29.03 | -27.65 | -25.32 | -26.31 | -21.30 |
Earnings Per Share Data | 1/31/24 | 10/31/23 | 7/31/23 | 4/30/23 | 1/31/23 |
---|---|---|---|---|---|
Average Shares | 34.72 | 34.57 | 34.41 | 34.34 | 28.28 |
Diluted EPS Before Non-Recurring Items | -0.84 | -0.80 | -0.74 | -0.77 | -0.75 |
Diluted Net EPS (GAAP) | -0.84 | -0.80 | -0.74 | -0.74 | -0.75 |